Samsara BioCapital’s IO Biotech IOBT Stock Holding History

Samsara BioCapital’s Portfolio IOBT Stock Details IOBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,640,015	Closed	-$3.82M	–	44
2024 Q3	$3.82M	Hold	3,640,015	–	–	0.73%	25
2024 Q2	$4.26M	Hold	3,640,015	–	–	0.89%	24
2024 Q1	$6.3M	Hold	3,640,015	–	–	0.97%	21
2023 Q4	$6.84M	Hold	3,640,015	–	–	1.06%	19
2023 Q3	$5.13M	Buy	3,640,015 +2,631,578	+261%	+$4.63M	1.57%	17
2023 Q2	$1.97M	Hold	1,008,437	–	–	0.35%	30
2023 Q1	$1.89M	Hold	1,008,437	–	–	0.39%	34
2022 Q4	$2.32M	Hold	1,008,437	–	–	0.5%	29
2022 Q3	$2.73M	Hold	1,008,437	–	–	0.64%	32
2022 Q2	$4.71M	Sell	1,008,437 -112,000	-10%	-$686K	1.26%	20
2022 Q1	$5.94M	Hold	1,120,437	–	–	1.49%	14
2021 Q4	$7.17M	Buy	+1,120,437	New	+$10.8M	1.39%	18

Other funds holding IOBT

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Samsara BioCapital's IOBT Position: Q4 2024 in Review

Samsara BioCapital sold out of IO Biotech (IOBT) in Q4 2024, closing a stake of 3,640,015 shares — an estimated $3.82M sold.

Samsara BioCapital first reported a position in IOBT in Q4 2021 and held it in 12 quarters. The position peaked at $7.17M in Q4 2021. 27 funds tracked by Wall St. Rank hold IOBT as of Q4 2024.

Samsara BioCapital reported no remaining IO Biotech position as of Q4 2024 after selling out during the quarter.
Samsara BioCapital sold 3,640,015 IO Biotech shares in Q4 2024, an estimated $3.82M.
Samsara BioCapital first reported a position in IO Biotech in Q4 2021 and held it in 12 quarters.
Samsara BioCapital's IO Biotech position peaked at $7.17M in Q4 2021.
27 funds tracked by Wall St. Rank held IO Biotech as of Q4 2024.

Based on Samsara BioCapital's 13F filing for Q4 2024, filed 14 Feb 2025.